A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer
- Conditions
- Gastric Cancer
- Interventions
- Biological: BemarituzumabDrug: PlaceboDrug: Modified FOLFOX6
- Registration Number
- NCT03694522
- Lead Sponsor
- Five Prime Therapeutics, Inc.
- Brief Summary
The main objective of the Phase 2 part of the study is to evaluate the efficacy of bemarituzumab (FPA144), a targeted antibody, in combination with modified FOLFOX6 compared to placebo in combination with modified FOLFOX6 in participants with advanced gastrointestinal cancer.
- Detailed Description
Study FPA144-004 is a phase 1/2, multicenter, global, double-blind, randomized, controlled study designed to evaluate the safety, tolerability, efficacy, and pharmacokinetics (PK) of bemarituzumab in combination with mFOLFOX6, compared with placebo in combination with mFOLFOX6, in adults with unresectable, locally advanced, or metastatic gastric cancer including cancer of the gastroesophageal junction (GEJ).
This study includes a Phase 1 safety run-in portion and a Phase 2 portion. The Phase 1 safety run-in is an open-label dose-escalation of bemarituzumab + mFOLFOX6 in patients with GI tumors (not FGFR2 selected) that is reported separately (NCT03343301).
The Phase 2 portion of the study (to follow the Phase 1 safety run-in) is described in this record.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 155
- Histologically documented gastric or gastroesophageal junctional adenocarcinoma (not amenable to curative therapy)
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Adequate hematological, liver and kidney function. Measurable or non-measurable, but evaluable disease using RECIST v1.1
- Fibroblast growth factor receptor 2b (FGFR2b) overexpression as determined by a centrally performed immunohistochemistry tissue test and/or FGFR2 gene amplification as determined by a centrally performed circulating tumor deoxyribonucleic acid (ctDNA) blood based assay
- Candidate for mFOLFOX6 chemotherapy
Key
- Untreated or symptomatic central nervous system (CNS) metastases
- Clinically significant cardiac disease,
- Peripheral sensory neuropathy >/= Common Terminology Criteria for Adverse Events (CTCAE) Grade 2
- Active infection requiring systemic treatment
- Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, or known active or chronic hepatitis B or C infection
- Prior treatment with any selective inhibitor of the fibroblast growth factor (FGF)-FGFR pathway
- Known abnormalities of the cornea that may pose an increased risk of developing a corneal ulcer
- Known positivity for human epidermal growth factor receptor 2 (HER2)
- Women who are pregnant or breastfeeding
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Bemarituzumab + mFOLFOX6 Modified FOLFOX6 Participants received 15 mg/kg bemarituzumab administered every 2 weeks (Q2W) with a single additional bemarituzumab 7.5 mg/kg dose on cycle 1 day 8. Participants also received mFOLFOX6 chemotherapy administered Q2W. Treatment continued until unacceptable toxicity, disease progression, or death. Bemarituzumab + mFOLFOX6 Bemarituzumab Participants received 15 mg/kg bemarituzumab administered every 2 weeks (Q2W) with a single additional bemarituzumab 7.5 mg/kg dose on cycle 1 day 8. Participants also received mFOLFOX6 chemotherapy administered Q2W. Treatment continued until unacceptable toxicity, disease progression, or death. Placebo + mFOLFOX6 Placebo Participants received placebo for bemarituzumab administered every 2 weeks with a single additional placebo dose on cycle 1 day 8. Participants also received mFOLFOX6 chemotherapy administered Q2W. Treatment continued until unacceptable toxicity, disease progression, or death. Placebo + mFOLFOX6 Modified FOLFOX6 Participants received placebo for bemarituzumab administered every 2 weeks with a single additional placebo dose on cycle 1 day 8. Participants also received mFOLFOX6 chemotherapy administered Q2W. Treatment continued until unacceptable toxicity, disease progression, or death.
- Primary Outcome Measures
Name Time Method Progression-Free Survival (PFS) From randomization until the primary analysis data cut-off date of 23 September 2020; median time on follow-up was 10.9 months. PFS was defined as time from randomization until the date of radiographic disease progression based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or death from any cause, whichever came first. PFS was analyzed using Kaplan-Meier methods. Participants with no progression or death, or who started new anticancer therapy before documented progression or death without documented progression, or who had ≥ 2 consecutive missing tumor assessments before documented progression or death without documented progression were censored on the date of last adequate tumor assessment. Participants with no baseline tumor assessment, were censored at the date of randomization.
The primary efficacy analysis was pre-specified to be conducted after at least 84 PFS events were observed.
- Secondary Outcome Measures
Name Time Method Overall Survival (OS) From randomization until the primary analysis data cut-off date of 23 September 2020; median time on follow-up was 10.9 months. OS is defined as time from randomization until death from any cause. Participants who were lost to follow-up or did not have a date of death were censored at the last date that they were known to be alive. Participants with confirmed death or alive status after the data cutoff date were censored at the data cutoff date. Median OS was estimated using a Kaplan-Meier analysis.
Number of Participants With Treatment-emergent Adverse Events (TEAEs) From first dose of study drug to 28 days after last dose of study drug. Actual median (min, max) duration of treatment emergent period was 29 (4.1, 157) weeks in the bemarituzumab + mFOLFOX6 group and 28 (4.3, 133) weeks in the placebo + mFOLFOX6 group. TEAEs are defined as adverse events (AEs) that started or worsened from the start of study drug to 28 days after permanent discontinuation of study drug.
A serious AE is defined as any untoward medical occurrence that:
* Resulted in death;
* Was life-threatening;
* Required inpatient hospitalization or prolongation of existing hospitalization;
* Resulted in persistent or significant disability or incapacity;
* Was a congenital anomaly or birth defect.
The investigator assessed the causality/relationship between study treatment and each AE, and assessed the severity of each AE according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 5.0 on a scale from mild (Grade 1), moderate (Grade 2), severe (Grade 3), life-threatening (Grade 4), or death due to the AE (Grade 5). Cornea and retina AEs were defined by Standardized Medical Dictionary for Regulatory Activities Queries (SMQs) of corneal disorders and retinal disorders (broad).Overall Response Rate (ORR) Tumor assessments were performed every 8 weeks until 12 months and then every 12 weeks thereafter until disease progression or additional anticancer therapy was initiated; the median duration of follow-up time was 10.9 months. Tumor response assessment was performed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 guidelines. ORR is defined as the percentage of participants who achieved a best overall response (BOR) of either complete response (CR) or partial response (PR) based on investigator assessment of tumor lesions per RECIST v1.1.
CR was defined as the disappearance of all lesions except lymph node short axis \< 10 mm; PR was defined as a ≥ 30% reduction in sum of diameters in target lesions.
Trial Locations
- Locations (189)
Virginia Mason Seattle Main Clinic
🇺🇸Seattle, Washington, United States
ASST della Valtellina e dell'Alto Lario - PO di Sondrio
🇮🇹Sondrio, Italy
National Cancer Center Hospital East
🇯🇵Kashiwa, Chiba, Japan
The Oncology Institute of Tuscon
🇺🇸Tucson, Arizona, United States
Tennessee Cancer Specialists
🇺🇸Knoxville, Tennessee, United States
Medical University of South Carolina
🇺🇸Charleston, South Carolina, United States
Beskidzkie Centrum Onkologii - Szpital Miejski im. Jana Pawla II w Bielsku-Bialej
🇵🇱Bielsko-Biala, Poland
Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie
🇵🇱Lublin, Poland
Centro Hospitalar de Entre o Douro e Vouga EPE
🇵🇹Santa Maria Da Feira, Portugal
Institutul Clinic Fundeni - Clinica Pediatrie
🇷🇴Bucharest, Romania
SC Oncolab SRL, Oncologie
🇷🇴Craiova, Romania
Summit Medical Group. Morristown Oncology
🇺🇸Morristown, New Jersey, United States
AZ Sint Jan
🇧🇪Brugge, Belgium
Hopital Nord France Comte - Site Le Mittan
🇫🇷Montbéliard, France
CHU de Saint Etienne
🇫🇷Saint-Étienne, France
Istituto Europeo di Oncologia
🇮🇹Milan, Italy
Instituto Portugues de Oncologia do Porto Francisco Gentil E.P.E
🇵🇹Porto, Portugal
Spitalul Clinic Judetean de Urgenta ,,Sf. Apostol Andrei" Constanta, Clinica Oncologie Medicala
🇷🇴Constanţa, Romania
University of Michigan Health System
🇺🇸Ann Arbor, Michigan, United States
Korea University Anam Hospital
🇰🇷Seoul, Korea, Republic of
CHC Clinique Saint-Joseph
🇧🇪Liege, Belgium
CHU UCL Namur, site Godinne
🇧🇪Yvoir, Belgium
Azienda Sanitaria Universitaria Integrata de Udine
🇮🇹Udine, Italy
Oschsner Clinic Foundation
🇺🇸New Orleans, Louisiana, United States
Unidade Local de Saude de Matosinhos EPE
🇵🇹Senhora Da Hora, Portugal
The Catholic University of Korea, Seoul St. Mary's Hospital
🇰🇷Seoul, Korea, Republic of
Dana-Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Cukurova University Faculty of Medicine Paediatric Nephrology
🇹🇷Adana, Turkey
Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Kyungpook National University Chilgok Hospital
🇰🇷Daegu, North Gyeongsang, Korea, Republic of
Institutul Oncologic, Prof. Dr. I. Chiricuta Cluj-Napoca
🇷🇴Cluj-Napoca, Romania
S.C. Centrul de Oncologie Sf. Nectarie S.R.L., Oncologie Medicala
🇷🇴Craiova, Romania
Uludag Universitesi Tip Fakultesi
🇹🇷Bursa, Turkey
Istanbul University Cerrahpasa Medical Faculty
🇹🇷Istanbul, Turkey
Medical Park Izmir Hastanesi
🇹🇷Izmir, Turkey
Ondokuz Mayis University Medicine Faculty
🇹🇷Atakum, Turkey
Adnan Menderes Universitesi Uygulama ve Arastirma Hastanesi
🇹🇷Aydin, Turkey
University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center)
🇺🇸Rochester, New York, United States
UCLA Medical Centre - Santa Monica Hematology and Oncology
🇺🇸Santa Monica, California, United States
Karmanos Cancer Institute
🇺🇸Detroit, Michigan, United States
Josephine Ford Cancer Center-Henry Ford Cancer Center
🇺🇸Detroit, Michigan, United States
Centre de Radiotherapie - Clinique Sainte Anne
🇫🇷Strasbourg, France
Centre Paul Strauss
🇫🇷Strasbourg, France
Stadtisches Klinikum Braunschweig
🇩🇪Braunschweig, Germany
Krankenhaus Nordwest gGmbH, Institut fur Klinisch-Onkologische Forschung
🇩🇪Frankfurt am Main, Germany
Klinikum Ostalb, Stauferklinikum Schwabisch Gmund, Zentrum fur Innere Medizin
🇩🇪Mutlangen, Germany
National Institute of Oncology
🇭🇺Budapest, Hungary
Kliniken Nordoberpfalz AG, Klinikum Weiden, Medizinische Klinik I
🇩🇪Oberpfalz, Germany
University of Pecs, Clinic of Oncotherapy
🇭🇺Pecs, Hungary
Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz - Rendelointezet
🇭🇺Szolnok, Hungary
Klinikum Ludwigsburg
🇩🇪Ludwigsburg, Germany
Universitatsmedizin Manheim, II. Medizinische Klinik
🇩🇪Mannheim, Germany
Sugarterapias es Klinikai Onkologaiai Intezet B-A-Z Megyei Korhaz
🇭🇺Miskolc, Hungary
Josa Andras Teaching Hospital
🇭🇺Nyíregyháza, Hungary
Klinik fur Innere Medizin, Shwerpunkt Gastroenterologie, Hamatologie, Onkologie, Nephrologie
🇩🇪Berlin, Germany
Del-Pesti Centrumkorhaz - Orszangos Hematologiai es Infektologiai Intezet, Onkologiai Osztaly
🇭🇺Budapest, Hungary
Hyogo College of Medicine College Hospital
🇯🇵Nishinomiya, Japan
AOU Ospedall Riuniti Umberto
🇮🇹Ancona, Italy
AO "S.G. Moscati"
🇮🇹Avellino, Italy
Centro di Riferimento Oncologico
🇮🇹Aviano, Italy
Azienda Ospedaliera Spedali Civili di Brescia-Universita degli Studi Di Brescia
🇮🇹Brescia, Italy
Istituto di Ricovero e Cura a Carattere Scientifico - IRCCS di Candiolo
🇮🇹Candiolo, Italy
Azienda Socio-Sanitaria Territoriale di Cremona
🇮🇹Cremona, Italy
Azienda Ospedaliero Universitaria Caregg - I S.O.D. Oncologia Medica
🇮🇹Firenze, Italy
Ospedale Policlinico S. Martino
🇮🇹Genova, Italy
Ospedale Generale Mater Salutis" - Azienda ULSS n. 21 di Legnago
🇮🇹Legnago, Italy
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
🇮🇹Meldola, Italy
Servizio Oncologia Medica ed Ematologia, AOU dell'Universita
🇮🇹Napoli, Italy
Fondazione Irccs Policlinico San Matteo
🇮🇹Pavia, Italy
Azienda Ospedaliera Universitaria Pisana
🇮🇹Pisa, Italy
Hospital del Mar
🇪🇸Barcelona, Spain
Fondazione IRCSS Casa Sollievo Della Sofferenza
🇮🇹San Giovanni Rotondo, Italy
Policlinico Universitario Campus Bio-Medico di Roma
🇮🇹Roma, Italy
A.O.U. Citta della Salute e della Scienza di Torino - Presidio Molinette
🇮🇹Torino, Italy
Kagawa University Hospital
🇯🇵Kita-gun, Kagawa, Japan
Japan Community Health Care Organization Kyushu Hospital
🇯🇵Kitakyushu, Japan
Kangbuk Samsung Hospital
🇰🇷Seoul, Korea, Republic of
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
🇯🇵Bunkyō-Ku, Japan
Dong-A University Hospital
🇰🇷Busan, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Hiroshima Citizens Hospital
🇯🇵Hiroshima, Japan
Osaka General Medical Center
🇯🇵Osaka, Japan
St. Marianna University School of Medicine Hospital
🇯🇵Kawasaki, Japan
The Cancer Institute Hospital of JFCR
🇯🇵Koto-Ku, Japan
Niigata Cancer Center Hospital
🇯🇵Niigata, Japan
Osaka Medical College Hospital
🇯🇵Osaka, Japan
Gangnam Severance Hospital, Yonsei University Health System
🇰🇷Seoul, Gangnam, Korea, Republic of
Hallym University Sacred Heart Hospital
🇰🇷Anyang, Gyeonggi-do, Korea, Republic of
Seoul National University Bundang Hospital
🇰🇷Seongnam, Gyeonggi, Korea, Republic of
Ajou University Hospital
🇰🇷Suwon, Gyeonggi, Korea, Republic of
Chonbuk National University Hospital
🇰🇷Jeonju, Jeollabuk-do, Korea, Republic of
Gachon University Gil Medical Center
🇰🇷Incheon, Namdong-gu, Korea, Republic of
Chungnam National University Hospital (CNUH)
🇰🇷Daejeon, Korea, Republic of
Szpital Specjalistyczny w Brzozowie, Podkarpacki Osrodek Onkologiczny
🇵🇱Brzozów, Poland
Lekarz Beata Madej Mruk I Partner. Spolka Partnerska Oddzial nr 1 w Rzesowie
🇵🇱Rzeszów, Poland
Korea University Guro Hospital
🇰🇷Seoul, Korea, Republic of
S.C. Oncocenter Oncologie Clinica S.R.L
🇷🇴Timisoara, Romania
SP ZOZ Ministerstwa Spraw Wewnetrznych z Warminsko - Mazurskim Centrum Onkologii
🇵🇱Olsztyn, Poland
Europejskie Centrum Zdrowia Otwock Szpital im. F. Chopina
🇵🇱Otwock, Poland
Wojskowy Instytut Medyczny, Centralny Szpital Kliniczny Ministerstwa Obronty Narodowej
🇵🇱Warszawa, Poland
Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie Klinika Onkologi I Radioterapii
🇵🇱Warszawa, Poland
Centro Hospitalar do Baixo Vouga, EPE
🇵🇹Aveiro, Portugal
Hospital de Braga
🇵🇹Braga, Portugal
Hospital Senhora Da Oliveira EPE
🇵🇹Guimarães, Portugal
Centro Hospitalar Universitario do Porto E.P.E
🇵🇹Porto, Portugal
S.C. Medisprof S.R.L
🇷🇴Cluj Napoca, Romania
China Medical University Hospital
🇨🇳Taichung, Taiwan
Khon Kaen Hospital
🇹🇭Khon Kaen, Thailand
Lampang Cancer Hospital
🇹🇭Lampang, Thailand
Hospital Universitari Arnau de Vilanova
🇪🇸Lleida, Spain
Complejo Hospitalario Universitario A Coruna
🇪🇸A Coruña, Spain
Hospital Universitario Fundacion Alcorcon
🇪🇸Alcorcon, Spain
Hospital de la Santa Creu I Sant Pau
🇪🇸Barcelona, Spain
Hospital Universitario Fundacion Jimenez Diaz
🇪🇸Madrid, Spain
Hospital Duran I Reynals - Instituto Catalan de Oncologia
🇪🇸Barcelona, Spain
Faculty of Medicine, Chulalongkorn University
🇹🇭Bankok, Thailand
Chiangrai Prachanukroh Hospital
🇹🇭Chiang Rai, Thailand
Faculty of Medicine, Prince of Sonkla University
🇹🇭Hat Yai, Thailand
Hacettepe Universitesi Tip Fakultesi
🇹🇷Ankara, Turkey
Gaziantep Universitesi Tip Fakultesi, Sahinbey Onkoloji Hastanesi
🇹🇷Gaziantep, Turkey
Ege University Hopsital
🇹🇷Izmir, Turkey
Kocaeli Universitesi Tip Fakultesi
🇹🇷Kocaeli, Turkey
Ankara Oncology Education and Research Hospital
🇹🇷Ankara, Turkey
Istanbul Madeniyet Universitesi Tip Fakultesi
🇹🇷Istanbul, Turkey
Inonu Universitesi Tip Fakultesi Turgut Ozal Tip Merkezi
🇹🇷Malatya, Turkey
Ninewells Hospital and Medical School
🇬🇧Dundee, United Kingdom
Yuzuncuyil Universitesi Tip Fakultesi
🇹🇷Van, Turkey
Clinica Universidad de Navarra
🇪🇸Pamplona, Spain
Hospital General de Catalunya
🇪🇸Barcelona, Spain
Institut Catala d'Oncologia - Hospital Doctor Josep Trueta
🇪🇸Girona, Spain
Hospital Universitario HM Sanchinarro
🇪🇸Madrid, Spain
Hospital General Universitario Gregorio Maranon
🇪🇸Madrid, Spain
Hosptial Universitario Virgen Macarena
🇪🇸Servilla, Spain
Complejo Hospital De Navarra
🇪🇸Pamplona, Spain
Hospital Universitario Mutua de Terrassa
🇪🇸Terrassa, Spain
Corporacio Sanitaria Parc Tauli
🇪🇸Sabadell, Spain
Ruijin Hospital Affiliated to Shanghai Jiatong University School of Medicine
🇨🇳Shanghai, China
Fourth Hospital of Hebei Medical University
🇨🇳Shijiazhuang, China
Henan Cancer Hospital
🇨🇳Zhengzhou, China
University of Arizona Cancer Center
🇺🇸Tucson, Arizona, United States
Marin Cancer Care, Inc-California Cancer Care A Medical Group, Inc
🇺🇸Greenbrae, California, United States
Sutter Medical Group
🇺🇸Sacramento, California, United States
Innovative Clinical Research Institute (ICRI)
🇺🇸Whittier, California, United States
Yale Cancer Center
🇺🇸New Haven, Connecticut, United States
Hartford Healthcare Cancer Institute at The Hospital of Central Connecticut
🇺🇸Plainville, Connecticut, United States
University of Chicago
🇺🇸Chicago, Illinois, United States
Northwestern Medicine Cancer Center Warrenville
🇺🇸Warrenville, Illinois, United States
Beth Israel Deaconess Medical Center
🇺🇸Boston, Massachusetts, United States
Stony Brook Cancer Center
🇺🇸Stony Brook, New York, United States
Westchester Institute For Treatment Of Cancer & Blood Disorders
🇺🇸White Plains, New York, United States
FirstHealth Outpatient Cancer Center
🇺🇸Pinehurst, North Carolina, United States
St. Luke's Physician Group - St. Luke's Cancer Care Associates
🇺🇸Bethlehem, Pennsylvania, United States
Arlington Cancer Center
🇺🇸Arlington, Texas, United States
Utah Cancer Specialists (Intermountain Hematology - Oncology Associates) UCS Cancer Center
🇺🇸S. Salt Lake, Utah, United States
Sydney Adventist Hospital
🇦🇺Wahroonga, Australia
Chris O'brien Lifehouse
🇦🇺Camperdown, Australia
The Townsville Hospital
🇦🇺Douglas, Australia
The Second Affiliated Hospital of Soochow University
🇨🇳Suzhou, China
CH de l'Ardenne
🇧🇪Libramont, Belgium
Anhui Provincial Cancer Hospital
🇨🇳Hefei, Anhui, China
Wuhan Union Hospital of China
🇨🇳Wuhan, Hubei, China
Shiyan Taihe Hospital
🇨🇳Shiyan, Hubei, China
Beijing Cancer Hospital
🇨🇳Beijing, China
The 81st Hospital of Chinese PLA
🇨🇳Nanjing, Jiangsu, China
Chinese PLA General Hospital
🇨🇳Beijing, China
The First Hospital of Jilin University
🇨🇳Changchun, China
Tianjin Medical University Cancer Institute and Hospital
🇨🇳Tianjin, China
Cancer Hospital of Shantou University Medical College
🇨🇳Shantou, China
Liaoning Cancer Hospital
🇨🇳Shenyang, China
Sino Japanese Friendship Hospital of Jilin University
🇨🇳Changchun, China
Hunan Cancer Hospital
🇨🇳Changsha, China
Xiangya Hospital of Central South University
🇨🇳Changsha, China
Chongqing Daping Hospital
🇨🇳Chongqing, China
The First Affiliated Hospital, Zhejiang University
🇨🇳Hangzhou, China
Zhejiang Cancer Hospital
🇨🇳Hangzhou, China
Sir Run Run Shaw Hospital
🇨🇳Hangzhou, China
Harbin Medical University Cancer Hopsital
🇨🇳Harbin, China
Nanton Tumor Hospital
🇨🇳Nantong, China
Shanghai East Hospital
🇨🇳Shanghai, China
Fudan University Shanghai Cancer Center
🇨🇳Shanghai, China
Hospital Universitario Puerta de Hierro Majadahonda
🇪🇸Majadahonda, Spain
CHRU Jean MINJOZ
🇫🇷Besançon, France
Chu Morvan - Institut de Cancerologie
🇫🇷Brest, France
Polyclinique de Gentilly
🇫🇷Nancy, France
Bezmialem Vakif Universitesi Tip Fakultesi Hastanesi
🇹🇷Istanbul, Turkey
UNC- Chapel Hill
🇺🇸Chapel Hill, North Carolina, United States
University of Kansas Medical Center
🇺🇸Westwood, Kansas, United States
Fujian Cancer Hospital
🇨🇳Fuzhou, China